Sridhar Natesan
Sridhar Natesan
Senior Researcher, Institute of Psychiatry, Psychology and Neuroscience, King's College London
Verified email at kcl.ac.uk
Title
Cited by
Cited by
Year
Dissociation between in vivo occupancy and functional antagonism of dopamine D 2 receptors: comparing aripiprazole to other antipsychotics in animal models
S Natesan, GE Reckless, JN Nobrega, PJ Fletcher, S Kapur
Neuropsychopharmacology 31 (9), 1854-1863, 2006
2052006
Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics?
RM Murray, D Quattrone, S Natesan, J van Os, M Nordentoft, O Howes, ...
The British Journal of Psychiatry 209 (5), 361-365, 2016
1702016
Effect of chronic antipsychotic treatment on brain structure: a serial magnetic resonance imaging study with ex vivo and postmortem confirmation
AC Vernon, S Natesan, M Modo, S Kapur
Biological psychiatry 69 (10), 936-944, 2011
1582011
Contrasting effects of haloperidol and lithium on rodent brain structure: a magnetic resonance imaging study with postmortem confirmation
AC Vernon, S Natesan, WR Crum, JD Cooper, M Modo, SCR Williams, ...
Biological psychiatry 71 (10), 855-863, 2012
1062012
Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a …
T Pillinger, RA McCutcheon, L Vano, Y Mizuno, A Arumuham, G Hindley, ...
The Lancet Psychiatry 7 (1), 64-77, 2020
1052020
Reduced cortical volume and elevated astrocyte density in rats chronically treated with antipsychotic drugs—linking magnetic resonance imaging findings to cellular pathology
AC Vernon, WR Crum, JP Lerch, W Chege, S Natesan, M Modo, ...
Biological psychiatry 75 (12), 982-990, 2014
932014
The dopamine stabilizers (S)-(-)-(3-methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-methanesulfonylphenyl)-1-propyl-piperidine (ACR16) show high in vivo D2 …
S Natesan, KA Svensson, GE Reckless, JN Nobrega, KBL Barlow, ...
Journal of Pharmacology and Experimental Therapeutics 318 (2), 810-818, 2006
922006
Loss of phosphodiesterase 10A expression is associated with progression and severity in Parkinson’s disease
F Niccolini, T Foltynie, T Reis Marques, N Muhlert, AC Tziortzi, GE Searle, ...
Brain 138 (10), 3003-3015, 2015
792015
Altered PDE10A expression detectable early before symptomatic onset in Huntington’s disease
F Niccolini, S Haider, T Reis Marques, N Muhlert, AC Tziortzi, GE Searle, ...
Brain 138 (10), 3016-3029, 2015
782015
Amisulpride the ‘atypical’atypical antipsychotic—comparison to haloperidol, risperidone and clozapine
S Natesan, GE Reckless, KBL Barlow, JN Nobrega, S Kapur
Schizophrenia research 105 (1-3), 224-235, 2008
732008
Microglial activation in the rat brain following chronic antipsychotic treatment at clinically relevant doses
MC Cotel, EM Lenartowicz, S Natesan, MM Modo, JD Cooper, ...
European Neuropsychopharmacology 25 (11), 2098-2107, 2015
682015
The antipsychotic potential of l-stepholidine—a naturally occurring dopamine receptor D 1 agonist and D 2 antagonist
S Natesan, GE Reckless, KBL Barlow, J Odontiadis, JN Nobrega, ...
Psychopharmacology 199 (2), 275-289, 2008
642008
Phosphodiesterase 10A PET radioligand development program: from pig to human
C Plisson, D Weinzimmer, S Jakobsen, S Natesan, C Salinas, SF Lin, ...
Journal of Nuclear Medicine 55 (4), 595-601, 2014
522014
Evaluation of N-desmethylclozapine as a potential antipsychotic—preclinical studies
S Natesan, GE Reckless, KBL Barlow, JN Nobrega, S Kapur
Neuropsychopharmacology 32 (7), 1540-1549, 2007
512007
Antipsychotics: mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology
SJ Kaar, S Natesan, R McCutcheon, OD Howes
Neuropharmacology 172, 107704, 2020
472020
Dynamic regulation of dopamine and serotonin responses to salient stimuli during chronic haloperidol treatment
D Amato, S Natesan, L Yavich, S Kapur, CP Müller
International Journal of Neuropsychopharmacology 14 (10), 1327-1339, 2011
472011
Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in rats
EC Onwordi, EF Halff, T Whitehurst, A Mansur, MC Cotel, L Wells, ...
Nature communications 11 (1), 1-11, 2020
382020
Partial agonists in schizophrenia–why some work and others do not: insights from preclinical animal models
S Natesan, GE Reckless, KBL Barlow, JN Nobrega, S Kapur
International Journal of Neuropsychopharmacology 14 (9), 1165-1178, 2011
362011
The effects of antipsychotic treatment on presynaptic dopamine synthesis capacity in first-episode psychosis: a positron emission tomography study
S Jauhar, M Veronese, MM Nour, M Rogdaki, P Hathway, S Natesan, ...
Biological psychiatry 85 (1), 79-87, 2019
302019
Regulation of dopaminergic function: an [18 F]-DOPA PET apomorphine challenge study in humans.
S Jauhar, M Veronese, M Rogdaki, M Bloomfield, S Natesan, ...
Translational psychiatry 7 (2), e1027-e1027, 2017
292017
The system can't perform the operation now. Try again later.
Articles 1–20